Antigen News and Research

RSS

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

The U.S. Patent and Trademark Office has issued to Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled "Methods and Compositions for Immunotherapy of Cancer," based upon patent application 10/949,667.

10 Sep 2010

Zebrafish DCs discovery provide researchers to investigate mammalian immune system

Scientists from the University of California, San Diego School of Medicine have identified dendritic antigen presenting cells in zebrafish, opening the possibility that the tiny fish could become a new model for studying the complexities of the human immune system.

9 Sep 2010

Scientists discover molecular gatekeeper for arthritis

Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report in a study published in the Journal of Experimental Medicine. The newly discovered gatekeeper is a protein that determines the fate survival or death of damaging cells that mistakenly attack the body's own tissues and lead to autoimmune disorders such as arthritis.

9 Sep 2010

Advaxis receives USPTO patent for Listeria vaccine

The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.

9 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Virginia G. Piper Cancer Center at Scottsdale Healthcare offers free prostate cancer screenings

Recognizing that early detection can save lives, the Virginia G. Piper Cancer Center at Scottsdale Healthcare is offering free prostate cancer screenings from 8:30 a.m.-12 p.m. on Saturday, Sept. 11.

3 Sep 2010

Research on immune system can develop new therapy for inflammation, tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

3 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

2 Sep 2010

Researchers find new fusion protein for E.coli bacterium vaccine development

South Dakota State University research is exploring a "fusion strategy" for making improved vaccines to protect pigs and humans against some strains of E. coli.

2 Sep 2010

Parkinson’s disease discoveries

Genes that affect the immune system and link it to Parkinson’s disease have been uncovered. This paves the way for new drug development in Parkinson’s disease – a serious, degenerative disease of the nerves that leads to tremors and muscle stiffness and eventually complete loss of movements. There is currently no cure for PD.

31 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

PCEC coordinates free or low-cost prostate cancer screenings as part of PCAW

A council of leading prostate cancer experts is working to protect the lives of American men by providing lifesaving prostate cancer screenings. The Prostate Conditions Education Council – a national organization committed to men's health and a leader in prostate cancer screening – is once again coordinating free or low-cost screenings as part of its national Prostate Cancer Awareness Week to help encourage men to protect their health.

30 Aug 2010

GWAS finds new genetic link between Parkinson's disease and inflammation

A hunt throughout the human genome for variants associated with common, late-onset Parkinson's disease has revealed a new genetic link that implicates the immune system and offers new targets for drug development.

30 Aug 2010

Affordable Care Act that mandates free preventative services goes into effect in September

Starting in September, President Obama's Affordable Care Act will go into effect. The act mandates free preventative services such as cholesterol or breast cancer screenings and tetanus shots. But the question is, will doctors and patients take advantage of these new preventative services? "Unfortunately, thanks to our American healthcare system, we have been programmed to focus on treatment and not prevention," said Dr. David Samadi, a urologic oncologist specializing in prostate cancer treatment and robotic surgery, who is also the Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

26 Aug 2010

Octapharma completes clinical development of Uniplas human pooled plasma

Octapharma AG, one of the largest private manufacturers of plasma products in the world, announced today that the clinical development for Uniplas® has been successfully completed. The product has been filed for registration in Europe and will be submitted later in the USA.

26 Aug 2010

Advaxis' 'Prokaryotic peptides for enhancing antigen immunogenicity' European patent application allowed

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania.

26 Aug 2010

USPTO to allow patent for Advaxis’s new vaccine technology

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."

21 Aug 2010